Your browser doesn't support javascript.
loading
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.
Kelemen, Linda E; Earp, Madalene; Fridley, Brooke L; Chenevix-Trench, Georgia; Fasching, Peter A; Beckmann, Matthias W; Ekici, Arif B; Hein, Alexander; Lambrechts, Diether; Lambrechts, Sandrina; Van Nieuwenhuysen, Els; Vergote, Ignace; Rossing, Mary Anne; Doherty, Jennifer A; Chang-Claude, Jenny; Behrens, Sabine; Moysich, Kirsten B; Cannioto, Rikki; Lele, Shashikant; Odunsi, Kunle; Goodman, Marc T; Shvetsov, Yurii B; Thompson, Pamela J; Wilkens, Lynne R; Dörk, Thilo; Antonenkova, Natalia; Bogdanova, Natalia; Hillemanns, Peter; Runnebaum, Ingo B; du Bois, Andreas; Harter, Philipp; Heitz, Florian; Schwaab, Ira; Butzow, Ralf; Pelttari, Liisa M; Nevanlinna, Heli; Modugno, Francesmary; Edwards, Robert P; Kelley, Joseph L; Ness, Roberta B; Karlan, Beth Y; Lester, Jenny; Orsulic, Sandra; Walsh, Christine; Kjaer, Susanne K; Jensen, Allan; Cunningham, Julie M; Vierkant, Robert A; Giles, Graham G; Bruinsma, Fiona.
Afiliação
  • Kelemen LE; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Kelemen@musc.edu.
  • Earp M; Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. Kelemen@musc.edu.
  • Fridley BL; Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN 55905, USA. madalene.earp@ucalgary.ca.
  • Chenevix-Trench G; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 USA. brooke.fridley@moffitt.org.
  • Fasching PA; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Beckmann MW; Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Ekici AB; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center, 91054 Erlangen, Germany. peter.fasching@uk-erlangen.de.
  • Hein A; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA. peter.fasching@uk-erlangen.de.
  • Lambrechts D; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center, 91054 Erlangen, Germany. fk-direktion@uk-erlangen.de.
  • Lambrechts S; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen 91054, Germany. arif.ekici@uk-erlangen.de.
  • Van Nieuwenhuysen E; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center, 91054 Erlangen, Germany. alexander.hein@uk-erlangen.de.
  • Vergote I; Vesalius Research Center, University of Leuven, Leuven 3001, Belgium. diether.lambrechts@vib-kuleuven.be.
  • Rossing MA; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven 3000, Belgium. diether.lambrechts@vib-kuleuven.be.
  • Doherty JA; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven 3000, Belgium. sandrina.lambrechts@mumc.nl.
  • Chang-Claude J; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven 3000, Belgium. els.vannieuwenhuysen@uzleuven.be.
  • Behrens S; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven 3000, Belgium. ignace.vergote@uzleuven.be.
  • Moysich KB; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. mrossing@fhcrc.org.
  • Cannioto R; Department of Epidemiology, University of Washington, Seattle, WA 98402, USA. mrossing@fhcrc.org.
  • Lele S; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA. jennifer.doherty@hci.utah.edu.
  • Odunsi K; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. j.chang-claude@dkfz-heidelberg.de.
  • Goodman MT; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. j.chang-claude@dkfz-heidelberg.de.
  • Shvetsov YB; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. s.behrens@dkfz.de.
  • Thompson PJ; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. moysich@roswellpark.org.
  • Wilkens LR; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. rikki.cannioto@roswellpark.org.
  • Dörk T; Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. shashi.lele@roswellpark.org.
  • Antonenkova N; Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. kunle.odunsi@roswellpark.org.
  • Bogdanova N; Department of Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. marc.goodman@cshs.org.
  • Hillemanns P; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. marc.goodman@cshs.org.
  • Runnebaum IB; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA. yshvetso@cc.hawaii.edu.
  • du Bois A; Department of Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. pamela.thompson@cshs.org.
  • Harter P; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. pamela.thompson@cshs.org.
  • Heitz F; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA. lynne@cc.hawaii.edu.
  • Schwaab I; Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany. doerk.thilo@mh-hannover.de.
  • Butzow R; Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk 223040, Belarus. antonenkova.natalia.omd@tut.by.
  • Pelttari LM; Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany. bogdanova.natalia@mh-hannover.de.
  • Nevanlinna H; Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover 30625, Germany. hillemanns.peter@mh-hannover.de.
  • Modugno F; Department of Gynecology, Jena University Hospital-Friedrich Schiller University, Jena 07743, Germany. ingo.runnebaum@med.uni-jena.de.
  • Edwards RP; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte (KEM), Essen 45136, Germany. prof.dubois@googlemail.com.
  • Kelley JL; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden 65199, Germany. prof.dubois@googlemail.com.
  • Ness RB; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte (KEM), Essen 45136, Germany. p.harter@gmx.de.
  • Karlan BY; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden 65199, Germany. p.harter@gmx.de.
  • Lester J; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte (KEM), Essen 45136, Germany. florian.heitz@gmx.net.
  • Orsulic S; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden 65199, Germany. florian.heitz@gmx.net.
  • Walsh C; Praxis für Humangenetik, Wiesbaden 65187, Germany. iraschwaab@gmx.de.
  • Kjaer SK; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland. ralf.butzow@hus.fi.
  • Jensen A; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland. ralf.butzow@hus.fi.
  • Cunningham JM; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland. liisa.pelttari@helsinki.fi.
  • Vierkant RA; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland. heli.nevanlinna@hus.fi.
  • Giles GG; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. fm@cs.cmu.edu.
  • Bruinsma F; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15213, USA. fm@cs.cmu.edu.
Int J Mol Sci ; 19(9)2018 08 21.
Article em En | MEDLINE | ID: mdl-30134598
Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3' gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97⁻1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03⁻1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10-28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Timidilato Sintase / Proteínas / Regulação Neoplásica da Expressão Gênica / RNA Antissenso / Adenocarcinoma Mucinoso / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Timidilato Sintase / Proteínas / Regulação Neoplásica da Expressão Gênica / RNA Antissenso / Adenocarcinoma Mucinoso / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos